bluebird bio Company Profile (NASDAQ:BLUE)

About bluebird bio (NASDAQ:BLUE)

bluebird bio logobluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BLUE
  • CUSIP: N/A
  • Web:
  • Market Cap: $5.86963 billion
  • Outstanding Shares: 45,589,000
Average Prices:
  • 50 Day Moving Avg: $108.37
  • 200 Day Moving Avg: $97.10
  • 52 Week Range: $37.05 - $136.85
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -18.03
  • P/E Growth: 0.29
Sales & Book Value:
  • Annual Revenue: $26.65 million
  • Price / Sales: 220.25
  • Book Value: $26.35 per share
  • Price / Book: 4.89
  • EBIDTA: ($259,890,000.00)
  • Net Margins: -1,080.59%
  • Return on Equity: -32.19%
  • Return on Assets: -25.23%
  • Current Ratio: 14.37%
  • Quick Ratio: 14.37%
  • Average Volume: 947,998 shs.
  • Beta: 2.04
  • Short Ratio: 8.97

Frequently Asked Questions for bluebird bio (NASDAQ:BLUE)

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) issued its earnings results on Wednesday, August, 2nd. The company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.66) by $0.07. The firm earned $16.70 million during the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The firm's revenue was up 977.4% compared to the same quarter last year. During the same period last year, the business earned ($1.59) EPS. View bluebird bio's Earnings History.

When will bluebird bio make its next earnings announcement?

bluebird bio is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for bluebird bio.

Where is bluebird bio's stock going? Where will bluebird bio's stock price be in 2017?

21 equities research analysts have issued 12-month price targets for bluebird bio's shares. Their predictions range from $39.00 to $158.00. On average, they anticipate bluebird bio's stock price to reach $107.33 in the next year. View Analyst Ratings for bluebird bio.

What are analysts saying about bluebird bio stock?

Here are some recent quotes from research analysts about bluebird bio stock:

  • 1. Cantor Fitzgerald analysts commented, "LentiGlobin R&D, A Costly Endeavor. From 2014 to 2016, LentiGlobin has accounted for approximately $127 million in direct R&D expenditures. While these expenditures for LentiGlobin have been substantial, they remain only a portion of total direct R&D ($240 million) and reported accounting R&D ($401 million). Given the 23 patients dosed with the gene therapy by ASH 2016, LentiGlobin amounted to an expense of $5.5 million per patient dosed. We estimate approximately 127 patients could be required to complete development for these programs, amounting to a cost of ~$700 million. We believe R&D estimates could accelerate and model for a slightly increased burn over future years." (7/24/2017)
  • 2. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (7/18/2017)
  • 3. BTIG Research analysts commented, "generally captured" data updates from ASCO and EHA. Positive On Outlook But Not Enough To Remain BullishMeanwhile, Bluebird has a "good lead" over the competition in drugs targeting anti-BCMA and a Phase 1 study of bb21217 will commence in the bottom half of 2017. But at the same time competitive efforts from rivals will also ramp up, including Kite Pharma Inc (NASDAQ: KITE), which will begin a study of a fully-human anti-BCMA CAR T therapy in the third quarter.The analyst remains "more optimistic than most" regarding the LentiGlobin program for Beta-thalassemia and Sickle-cell disease. Also, the company's broadening of its oncology efforts may be a source of concern among some investors but early success in bb2121 is indeed supportive of a "broader effort in larger markets with better defined patient populations." (6/30/2017)
  • 4. Maxim Group analysts commented, "bluebird announced updated data at the ongoing ASCO (American Society of Clinical Oncology) meeting for bb2121 CAR-T in the CRB-401 Phase 1 study targeting relapsed/refractory multiple myeloma (r/r/ MM)." (6/2/2017)

Who are some of bluebird bio's key competitors?

Who are bluebird bio's key executives?

bluebird bio's management team includes the folowing people:

  • Daniel S. Lynch, Independent Chairman of the Board
  • Nick Leschly, President, Chief Executive Officer, Director
  • Jeffrey T. Walsh, Chief Financial and Strategy Officer and Principal Financial Officer, Principal Accounting Officer
  • Susanna Gatti High, Chief Operating Officer
  • Philip D. Gregory Ph.D., Chief Scientific Officer
  • David M. Davidson M.D., Chief Medical Officer
  • Jason F. Cole Esq., Chief Legal Officer, Secretary
  • John O. Agwunobi M.D., Director
  • Mary Lynne Hedley Ph.D., Director
  • Douglas A. Melton, Director

Who owns bluebird bio stock?

bluebird bio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (14.73%), Capital Research Global Investors (12.03%), Baillie Gifford & Co. (11.86%), Vanguard Group Inc. (7.81%), BlackRock Inc. (7.29%) and State Street Corp (3.19%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly and Philip D Gregory. View Institutional Ownership Trends for bluebird bio.

Who sold bluebird bio stock? Who is selling bluebird bio stock?

bluebird bio's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Balyasny Asset Management LLC, State Street Corp, Columbus Circle Investors, Jennison Associates LLC, AXA, Candriam Luxembourg S.C.A. and Wells Fargo & Company MN. Company insiders that have sold bluebird bio stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly and Philip D Gregory. View Insider Buying and Selling for bluebird bio.

Who bought bluebird bio stock? Who is buying bluebird bio stock?

bluebird bio's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Capital Research Global Investors, Vanguard Group Inc., Voya Investment Management LLC, Laurion Capital Management LP, Baillie Gifford & Co., Marshall Wace North America L.P. and BlackRock Inc.. View Insider Buying and Selling for bluebird bio.

How do I buy bluebird bio stock?

Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is bluebird bio's stock price today?

One share of bluebird bio stock can currently be purchased for approximately $128.75.

MarketBeat Community Rating for bluebird bio (NASDAQ BLUE)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  596 (Vote Outperform)
Underperform Votes:  208 (Vote Underperform)
Total Votes:  804
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for bluebird bio (NASDAQ:BLUE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 6 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.52)
Consensus Price Target: $107.33 (16.64% downside)

Analysts' Ratings History for bluebird bio (NASDAQ:BLUE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017Barclays PLCInitiated CoverageOverweight$151.00LowView Rating Details
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform -> Outperform$134.00 -> $158.00MediumView Rating Details
9/1/2017WedbushReiterated RatingOutperform$121.00 -> $135.00HighView Rating Details
8/31/2017Cowen and CompanyReiterated RatingOutperformHighView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$102.00HighView Rating Details
8/11/2017Jefferies Group LLCReiterated RatingBuy$88.00MediumView Rating Details
8/9/2017Morgan StanleyReiterated RatingHoldHighView Rating Details
8/4/2017BMO Capital MarketsReiterated RatingBuy$108.00MediumView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$109.00HighView Rating Details
7/24/2017Cantor FitzgeraldReiterated RatingSell$39.00HighView Rating Details
6/30/2017BTIG ResearchDowngradeBuy -> Neutral$37.05 -> $108.25MediumView Rating Details
6/26/2017Janney Montgomery ScottSet Price TargetBuy$125.00N/AView Rating Details
6/16/2017Standpoint ResearchReiterated RatingBuy -> Reduce$110.00LowView Rating Details
6/5/2017Bank of America CorporationReiterated RatingHold$95.00HighView Rating Details
6/2/2017Maxim GroupUpgradeHold -> Buy$100.00HighView Rating Details
2/23/2017Roth CapitalSet Price TargetHold$71.00N/AView Rating Details
12/7/2016J P Morgan Chase & CoReiterated RatingBuy$120.00N/AView Rating Details
12/1/2016Leerink SwannBoost Price TargetOutperform$80.00 -> $85.00N/AView Rating Details
11/30/2016Piper Jaffray CompaniesReiterated RatingOverweight$95.00N/AView Rating Details
10/15/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$135.00N/AView Rating Details
10/14/2016SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
11/5/2015Oppenheimer Holdings, Inc.Reiterated RatingOutperform$162.00N/AView Rating Details
(Data available from 9/26/2015 forward)


Earnings History for bluebird bio (NASDAQ:BLUE)
Earnings by Quarter for bluebird bio (NASDAQ:BLUE)
Earnings History by Quarter for bluebird bio (NASDAQ BLUE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($1.68)N/AView Earnings Details
8/2/2017Q2 2017($1.66)($1.73)$6.29 million$16.70 millionViewN/AView Earnings Details
5/3/2017Q1 2017($1.76)($1.68)$1.51 million$6.83 millionViewN/AView Earnings Details
2/22/2017Q4 2016($1.86)($1.88)$1.76 million$1.55 millionViewN/AView Earnings Details
11/2/2016Q3 2016($1.59)($2.07)$1.82 million$1.55 millionViewN/AView Earnings Details
8/3/2016Q2($1.44)($1.59)$2.01 million$1.55 millionViewN/AView Earnings Details
5/4/2016Q1($1.23)($1.52)$4.50 million$1.50 millionViewN/AView Earnings Details
2/24/2016Q4($1.11)($1.29)$3.21 million$1.47 millionViewN/AView Earnings Details
11/4/2015Q3($0.96)($1.18)$5.63 million$1.30 millionViewListenView Earnings Details
8/6/2015Q215($0.78)($1.57)$8.60 million$4.94 millionViewN/AView Earnings Details
5/6/2015Q115($0.68)($0.76)$6.20 million$6.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.62)($0.66)$6.20 million$6.30 millionViewN/AView Earnings Details
11/12/2014Q314($0.52)($0.61)$6.20 million$6.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.45)($0.06)$6.15 million$6.30 millionViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.44)$6.23 million$6.30 millionViewN/AView Earnings Details
3/5/2014($0.31)($0.34)ViewN/AView Earnings Details
11/12/2013Q3($0.25)($0.26)$5.59 million$6.39 millionViewN/AView Earnings Details
8/8/2013Q213($0.35)($2.13)$4.85 million$6.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for bluebird bio (NASDAQ:BLUE)
2017 EPS Consensus Estimate: ($7.28)
2018 EPS Consensus Estimate: ($7.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($1.88)($1.79)($1.83)
Q2 20175($1.89)($1.60)($1.75)
Q3 20175($1.94)($1.73)($1.82)
Q4 20175($2.03)($1.78)($1.88)
Q1 20181($1.78)($1.78)($1.78)
Q2 20181($1.81)($1.81)($1.81)
Q3 20181($1.84)($1.84)($1.84)
Q4 20181($1.87)($1.87)($1.87)
(Data provided by Zacks Investment Research)


Dividend History for bluebird bio (NASDAQ:BLUE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for bluebird bio (NASDAQ:BLUE)
Insider Ownership Percentage: 3.90%
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)
Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2017John MaraganoreDirectorSell18,868$131.21$2,475,670.28View SEC Filing  
9/12/2017Mark VachonDirectorSell6,000$126.82$760,920.00View SEC Filing  
9/11/2017Jeffrey T WalshInsiderSell4,900$125.73$616,077.00View SEC Filing  
9/1/2017Nick LeschlyInsiderSell46,833$122.27$5,726,270.91View SEC Filing  
8/31/2017Daniel LynchDirectorSell500$120.00$60,000.00View SEC Filing  
8/31/2017Jeffrey T WalshInsiderSell12,000$125.01$1,500,120.00View SEC Filing  
8/30/2017Nick LeschlyInsiderSell25,667$115.18$2,956,325.06View SEC Filing  
8/28/2017Jeffrey T WalshInsiderSell1,250$107.06$133,825.00View SEC Filing  
8/14/2017James MandellDirectorSell1,000$95.95$95,950.00View SEC Filing  
8/10/2017Jeffrey T WalshInsiderSell1,250$95.41$119,262.50View SEC Filing  
8/7/2017Philip D GregoryInsiderSell750$99.00$74,250.00View SEC Filing  
8/4/2017Eric SullivanInsiderSell861$93.83$80,787.63View SEC Filing  
8/1/2017David DavidsonInsiderSell3,000$92.37$277,110.00View SEC Filing  
7/10/2017Jeffrey T WalshInsiderSell2,500$99.89$249,725.00View SEC Filing  
7/7/2017David DavidsonInsiderSell1,200$100.49$120,588.00View SEC Filing  
7/6/2017Philip D GregoryInsiderSell2,250$103.83$233,617.50View SEC Filing  
7/5/2017David DavidsonInsiderSell5,000$105.28$526,400.00View SEC Filing  
6/29/2017Eric SullivanInsiderSell6,787$108.96$739,511.52View SEC Filing  
6/27/2017Nick LeschlyInsiderSell25,000$108.05$2,701,250.00View SEC Filing  
6/23/2017Daniel LynchDirectorSell4,000$109.09$436,360.00View SEC Filing  
6/20/2017Daniel LynchDirectorSell2,500$120.03$300,075.00View SEC Filing  
6/7/2017Jason ColeInsiderSell17,245$100.22$1,728,293.90View SEC Filing  
6/6/2017Daniel LynchDirectorSell2,263$100.14$226,616.82View SEC Filing  
6/6/2017Philip D GregoryInsiderSell1,500$99.04$148,560.00View SEC Filing  
6/5/2017David DavidsonInsiderSell1,000$90.00$90,000.00View SEC Filing  
5/25/2017Daniel LynchDirectorSell2,000$80.00$160,000.00View SEC Filing  
4/27/2017Daniel LynchDirectorSell1,000$90.01$90,010.00View SEC Filing  
4/25/2017Daniel LynchDirectorSell2,000$86.75$173,500.00View SEC Filing  
4/10/2017Jeffrey T WalshInsiderSell1,250$87.38$109,225.00View SEC Filing  
4/3/2017David DavidsonInsiderSell3,000$90.89$272,670.00View SEC Filing  
3/27/2017Daniel LynchDirectorSell3,000$88.12$264,360.00View SEC Filing  
3/16/2017Daniel LynchDirectorSell237$100.07$23,716.59View SEC Filing  
3/16/2017Jason ColeInsiderSell4,930$100.07$493,345.10View SEC Filing  
3/3/2017John MaraganoreDirectorSell13,839$85.02$1,176,591.78View SEC Filing  
2/15/2017Daniel LynchDirectorSell150$80.22$12,033.00View SEC Filing  
2/15/2017Jason ColeInsiderSell666$80.22$53,426.52View SEC Filing  
2/14/2017Daniel LynchDirectorSell850$80.01$68,008.50View SEC Filing  
2/14/2017Jason ColeInsiderSell3,772$80.01$301,797.72View SEC Filing  
1/31/2017James MandellDirectorSell8,000$75.04$600,320.00View SEC Filing  
1/27/2017Daniel LynchDirectorSell1,000$70.09$70,090.00View SEC Filing  
1/27/2017David DavidsonInsiderSell6,000$69.02$414,120.00View SEC Filing  
1/5/2017Jason ColeInsiderSell549$67.10$36,837.90View SEC Filing  
10/3/2016Eric SullivanInsiderSell416$67.00$27,872.00View SEC Filing  
9/13/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
8/3/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
7/27/2016Eric SullivanInsiderSell2,912$55.01$160,189.12View SEC Filing  
7/20/2016Eric SullivanInsiderSell2,807$45.04$126,427.28View SEC Filing  
7/15/2016David DavidsonInsiderSell1,000$45.08$45,080.00View SEC Filing  
6/16/2016Philip D GregoryInsiderSell2,931$39.52$115,833.12View SEC Filing  
6/15/2016David DavidsonInsiderSell1,000$40.11$40,110.00View SEC Filing  
5/16/2016David DavidsonInsiderSell1,000$38.73$38,730.00View SEC Filing  
4/15/2016David DavidsonInsiderSell1,000$49.63$49,630.00View SEC Filing  
3/15/2016David DavidsonInsiderSell1,000$46.13$46,130.00View SEC Filing  
2/16/2016David DavidsoninsiderSell1,000$45.18$45,180.00View SEC Filing  
1/15/2016David DavidsoninsiderSell1,000$44.39$44,390.00View SEC Filing  
12/15/2015David DavidsoninsiderSell1,000$58.55$58,550.00View SEC Filing  
12/8/2015Nick LeschlyCEOBuy9,682$51.75$501,043.50View SEC Filing  
11/16/2015David DavidsoninsiderSell2,000$70.99$141,980.00View SEC Filing  
11/10/2015Jeffrey T. WalshCOOSell11,000$74.60$820,600.00View SEC Filing  
10/15/2015David DavidsoninsiderSell2,000$79.70$159,400.00View SEC Filing  
10/12/2015Jeffrey T. WalshCOOSell11,000$88.06$968,660.00View SEC Filing  
10/9/2015Jason ColeSVPSell5,000$86.91$434,550.00View SEC Filing  
10/5/2015Daniel LynchDirectorSell3,000$100.41$301,230.00View SEC Filing  
9/17/2015Daniel LynchDirectorSell1,500$140.06$210,090.00View SEC Filing  
9/15/2015David DavidsoninsiderSell2,000$129.98$259,960.00View SEC Filing  
9/10/2015Jeffrey T. WalshCOOSell11,000$130.02$1,430,220.00View SEC Filing  
9/9/2015Jason ColeSVPSell2,000$136.56$273,120.00View SEC Filing  
9/8/2015Daniel LynchDirectorSell7,000$132.75$929,250.00View SEC Filing  
9/8/2015Nick LeschlyCEOSell125,000$135.24$16,905,000.00View SEC Filing  
9/1/2015James MandellDirectorSell1,500$125.96$188,940.00View SEC Filing  
7/20/2015Eric SullivanInsiderSell1,126$163.36$183,943.36View SEC Filing  
7/15/2015David DavidsonInsiderSell2,000$165.96$331,920.00View SEC Filing  
7/10/2015Jeffrey T WalshCOOSell11,000$158.63$1,744,930.00View SEC Filing  
7/9/2015Jason ColeSVPSell5,000$158.19$790,950.00View SEC Filing  
6/15/2015David DavidsonInsiderSell2,000$183.34$366,680.00View SEC Filing  
6/10/2015Jeffrey T WalshCOOSell11,000$179.70$1,976,700.00View SEC Filing  
6/1/2015Mitchell H FinerInsiderSell15,000$190.25$2,853,750.00View SEC Filing  
4/20/2015Mitchell H FinerInsiderSell15,000$126.03$1,890,450.00View SEC Filing  
4/15/2015David DavidsonInsiderSell2,000$130.18$260,360.00View SEC Filing  
4/10/2015Jeffrey T WalshCOOSell21,000$126.21$2,650,410.00View SEC Filing  
4/2/2015Eric SullivanInsiderSell2,998$117.81$353,194.38View SEC Filing  
3/10/2015Jeffrey T WalshCOOSell10,500$110.06$1,155,630.00View SEC Filing  
3/2/2015David DavidsonInsiderSell4,000$94.84$379,360.00View SEC Filing  
1/12/2015Jeffrey T WalshCOOSell10,500$103.57$1,087,485.00View SEC Filing  
1/2/2015David DavidsonInsiderSell4,000$90.01$360,040.00View SEC Filing  
12/19/2014John MaraganoreDirectorBuy2,352$85.00$199,920.00View SEC Filing  
12/10/2014Jeffrey T WalshCOOSell43,500$78.06$3,395,610.00View SEC Filing  
12/8/2014David DavidsonInsiderSell15,000$46.10$691,500.00View SEC Filing  
12/3/2014David DavidsonInsiderSell3,000$41.65$124,950.00View SEC Filing  
12/1/2014Mitchell H FinerInsiderSell18,000$39.70$714,600.00View SEC Filing  
12/1/2014Nick LeschlyCEOSell2,417$39.70$95,954.90View SEC Filing  
11/3/2014David DavidsonInsiderSell3,000$41.68$125,040.00View SEC Filing  
11/3/2014Nick LeschlyCEOSell25,000$41.68$1,042,000.00View SEC Filing  
10/24/2014Nick LeschlyCEOSell33,900$40.22$1,363,458.00View SEC Filing  
10/10/2014Jeffrey T WalshCOOSell7,500$33.16$248,700.00View SEC Filing  
10/9/2014Steven GillisDirectorSell115,000$35.25$4,053,750.00View SEC Filing  
10/8/2014Mitchell H FinerInsiderSell34,518$33.52$1,157,043.36View SEC Filing  
10/7/2014Steven GillisDirectorSell57,435$35.43$2,034,922.05View SEC Filing  
10/2/2014Steven GillisDirectorSell91,165$35.28$3,216,301.20View SEC Filing  
10/1/2014David DavidsonInsiderSell3,000$34.55$103,650.00View SEC Filing  
10/1/2014Nick LeschlyCEOSell8,000$34.55$276,400.00View SEC Filing  
9/12/2014Robert I TepperDirectorSell125,000$36.54$4,567,500.00View SEC Filing  
9/10/2014Jeffrey T WalshCOOSell7,500$37.02$277,650.00View SEC Filing  
9/2/2014David DavidsonInsiderSell3,000$38.00$114,000.00View SEC Filing  
9/2/2014Nick LeschlyCEOSell10,300$38.45$396,035.00View SEC Filing  
8/11/2014Jeffrey T WalshCOOSell7,500$34.26$256,950.00View SEC Filing  
8/1/2014David DavidsonInsiderSell3,000$33.62$100,860.00View SEC Filing  
8/1/2014Nick LeschlyCEOSell8,000$33.62$268,960.00View SEC Filing  
7/14/2014John MaraganoreDirectorBuy2,941$34.00$99,994.00View SEC Filing  
7/10/2014Jeffrey T WalshCOOSell7,500$33.20$249,000.00View SEC Filing  
7/3/2014Nick LeschlyCEOSell22,283$39.86$888,200.38View SEC Filing  
7/1/2014David DavidsonInsiderSell3,000$39.55$118,650.00View SEC Filing  
6/20/2014Nick LeschlyCEOSell17,075$40.06$684,024.50View SEC Filing  
6/16/2014Jeffrey T WalshCOOSell1,500$39.86$59,790.00View SEC Filing  
6/16/2014Mitchell H FinerInsiderSell10,000$39.84$398,400.00View SEC Filing  
6/16/2014Nick LeschlyCEOSell42,925$40.02$1,717,858.50View SEC Filing  
6/10/2014Jeffrey T WalshCOOSell6,000$24.23$145,380.00View SEC Filing  
6/2/2014Mitchell H FinerInsiderSell8,000$22.21$177,680.00View SEC Filing  
6/2/2014Nick LeschlyCEOSell5,000$22.21$111,050.00View SEC Filing  
5/14/2014Jeffrey WalshCOOSell1,500$20.03$30,045.00View SEC Filing  
5/12/2014Jeffrey WalshCOOSell4,500$18.93$85,185.00View SEC Filing  
5/1/2014David DavidsonInsiderSell4,000$19.85$79,400.00View SEC Filing  
5/1/2014Nick LeschlyCEOSell5,000$20.07$100,350.00View SEC Filing  
4/10/2014Jeffrey WalshCOOSell6,000$21.29$127,740.00View SEC Filing  
1/22/2014Linda BainVPSell2,500$25.11$62,775.00View SEC Filing  
1/17/2014Robert TepperDirectorSell307,000$22.43$6,886,010.00View SEC Filing  
1/16/2014Mitchell FinerInsiderSell10,000$23.52$235,200.00View SEC Filing  
1/14/2014Robert TepperDirectorSell340,000$21.90$7,446,000.00View SEC Filing  
1/10/2014Jeffrey WalshCOOSell6,000$21.98$131,880.00View SEC Filing  
1/3/2014David DavidsonInsiderSell15,000$20.88$313,200.00View SEC Filing  
1/3/2014Linda BainVPSell5,000$20.89$104,450.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for bluebird bio (NASDAQ:BLUE)
Latest Headlines for bluebird bio (NASDAQ:BLUE)
DateHeadline logoReviewing bluebird bio (BLUE) & Aldeyra Therapeutics (ALDX) - September 23 at 8:32 PM logobluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors - September 20 at 5:27 PM logobluebird bio, Inc. (BLUE) Director Sells $2,475,670.28 in Stock - September 18 at 7:22 PM logobluebird bio, Inc. (BLUE) Director Mark Vachon Sells 6,000 Shares - September 14 at 10:52 PM logobluebird bio (BLUE) Reports First Patient Treated in Expansion ... - - September 14 at 5:15 PM logoInsider Selling: bluebird bio, Inc. (BLUE) Insider Sells 4,900 Shares of Stock - September 13 at 7:38 PM logobluebird bio (BLUE) Reports First Patient Treated in Expansion Cohort of CRB-401, Phase 1 Study of Anti-BCMA CAR T Therapy bb2121 - September 13 at 5:49 PM logobluebird bio Announces First Patient Treated in Expansion Cohort of CRB-401, Phase 1 Study of Anti-BCMA CAR T Therapy bb2121 - September 13 at 5:49 PM logobluebird bio, Inc. (BLUE) Given Average Recommendation of "Hold" by Brokerages - September 13 at 3:16 PM logoIs bluebird bio Overvalued? - Seeking Alpha - September 11 at 5:18 PM logoZacks: Analysts Anticipate bluebird bio, Inc. (BLUE) Will Announce Quarterly Sales of $9.71 Million - September 9 at 1:04 AM logo Brokerages Expect bluebird bio, Inc. (BLUE) to Announce -$1.59 Earnings Per Share - September 7 at 10:24 PM logobluebird bio to Present Interim Clinical Data from Starbeam Study of ... - Business Wire (press release) - September 7 at 2:43 AM logoHere's What Lifted bluebird bio Inc. Stock 40% Higher in August - Motley Fool - September 7 at 2:43 AM logobluebird bio, Inc. (BLUE) Now Covered by Analysts at Barclays PLC - September 6 at 5:16 PM logobluebird bio (BLUE) to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in CALD at CNS Meeting - September 6 at 4:38 PM logobluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy (CALD) at Child Neurology Society (CNS) 2017 Annual Meeting - September 6 at 4:38 PM logoHere's What Lifted bluebird bio Inc. Stock 40% Higher in August - September 6 at 4:38 PM logobluebird bio, Inc. (BLUE) Insider Jeffrey T. Walsh Sells 12,000 Shares - September 5 at 7:22 PM logoInsider Selling: bluebird bio, Inc. (BLUE) Director Sells 500 Shares of Stock - September 5 at 4:46 PM logobluebird bio, Inc. (BLUE) Insider Nick Leschly Sells 46,833 Shares - September 5 at 4:26 PM logobluebird bio, Inc. (BLUE) Earns "Outperform" Rating from Wells Fargo & Company - September 5 at 12:20 PM logobluebird bio (BLUE) Looks Good: Stock Adds 11% in Session - September 1 at 4:53 PM logobluebird bio to Present at Investor Conferences in September - September 1 at 4:53 PM logoWedbush Reaffirms "Outperform" Rating for bluebird bio, Inc. (BLUE) - September 1 at 10:36 AM logoWhy bluebird bio Inc Continued Its March Higher Again Today - Motley Fool - August 31 at 9:36 PM logoETFs with exposure to bluebird bio, Inc. : August 31, 2017 - August 31 at 9:36 PM logoCowen and Company Reaffirms Outperform Rating for bluebird bio, Inc. (BLUE) - August 31 at 9:28 PM logobluebird bio, Inc. (BLUE) Insider Sells $2,956,325.06 in Stock - August 31 at 7:20 PM logoWhy bluebird bio Inc Continued Its March Higher Again Today - August 31 at 4:32 PM logobluebird bio, Inc. (BLUE) PT Raised to $300,000.00 - August 31 at 11:22 AM logoFDA Approves Treatment That Modifies Patient's Own Genes To Fight Cancer - August 31 at 4:04 AM logoKite Pharma Acquired - bluebird bio Remains Undervalued - Seeking Alpha - August 30 at 11:00 PM logoWhy bluebird bio Inc Jumped Higher Today - Motley Fool - August 30 at 11:00 PM logoInsider Selling: bluebird bio, Inc. (BLUE) Insider Sells 1,250 Shares of Stock - August 30 at 8:26 PM logoNovartis gene therapy approval signals new cancer treatment era - August 30 at 5:57 PM logoNovartis gene therapy approval signals new cancer treatment era - August 30 at 5:57 PM logoNovartis Wins FDA Approval for CAR-T; So Why Is Gilead Getting a Boost? - August 30 at 5:57 PM logoNovartis Wins FDA Approval for CAR-T; So Why Is Gilead Getting a Boost? - August 30 at 5:57 PM logoNovartis: A New $475,000 Drug - August 30 at 5:57 PM logoGilead Finally Pulls The Trigger With $12-Billion Kite Deal - August 29 at 4:57 PM logoToday's Research Reports on Trending Tickers: bluebird bio Inc. and Juno Therapeutics Inc. - August 29 at 4:56 PM logobluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : August 29, 2017 - August 29 at 4:56 PM logoJuno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition - August 29 at 4:56 PM logoGilead to buy Kite for promising cancer therapies in $12 billion deal - August 28 at 4:34 PM logoRecent GILD News - August 28 at 4:34 PM logoBiotech stocks surge on Gilead's Kite Pharma acquisition - August 28 at 4:34 PM logoGilead: What the Heck is CAR-T, How Much is Too Much, and Other Kite Acquisition Questions - August 28 at 4:34 PM logobluebird bio, Inc. to Post FY2017 Earnings of ($7.15) Per Share, Cantor Fitzgerald Forecasts (BLUE) - August 28 at 3:18 AM logobluebird bio, Inc. :BLUE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 - August 24 at 4:41 PM



bluebird bio (BLUE) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by Staff